Cryptocurrency exchange CoinFlex announced that it would issue up to $47 million of recovery tokens as the firm looks to resume withdrawals after halting them in the wake of a large account running into difficulties. The exchange halted customer withdrawals in mid-June, revealing in a whitepaper[1]yesterday that the issue stemmed

Brazils largest digital bank, Nubank, has rolled out bitcoin buying capabilities to all its 53.9 million customers[1]. The Warren Buffett-backed fintech had announced the feature in May[2] through a blog post, mentioning how the option would be rolled out in phases. At the time, the company also made a treasury

jax10289/iStock Editorial via Getty Images Investors have had to endure a tough year thus far, with the S&P 500 (SPY) and Nasdaq (QQQ) diving into bear market territory, and despite the terrible performance of the restaurant industry (EATZ) leading into 2022, it hasn’t been spared (negative 24% year-to-date). Fortunately, investors

Allogene Therapeutics’ (ALLO) goal of being a pioneer in the CAR-T field may be concerning for investors, given that CAR-T has been the worst performer in an already dismal healthcare market. So, let’s evaluate if it’s worth buying the stock now. Keep reading. shutterstock.com – StockNews Allogene Therapeutics, Inc. (ALLO)

Citigroup has decided to maintain its Buy rating of Autohome (NYSE:ATHM[1]) and raise its price target from $33.00 to $41.00. Shares of Autohome are trading up 6.17% over the last 24 hours, at $38.27 per share. A move to $41.00 would account for a 7.13% increase from the current share